Is Lineage Cell Stock a Good Investment?
Lineage Cell Investment Advice | LCTX |
- Examine Lineage Cell's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Lineage Cell's leadership team and their track record. Good management can help Lineage Cell navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Lineage Cell's business and its evolving consumer preferences.
- Compare Lineage Cell's performance and market position to its competitors. Analyze how Lineage Cell is positioned in terms of product offerings, innovation, and market share.
- Check if Lineage Cell pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Lineage Cell's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Lineage Cell Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Lineage Cell Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Lineage Cell Stock
Researching Lineage Cell's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 54.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.5. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Lineage Cell Therapeutics recorded a loss per share of 0.09. The entity had not issued any dividends in recent years. The firm had 3:1 split on the 31st of October 1997.
To determine if Lineage Cell is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Lineage Cell's research are outlined below:
| Lineage Cell had very high historical volatility over the last 90 days | |
| Lineage Cell has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 9.5 M. Net Loss for the year was (18.61 M) with loss before overhead, payroll, taxes, and interest of (3.31 M). | |
| Lineage Cell Therapeutics currently holds about 66.36 M in cash with (23.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39. | |
| Lineage Cell has a frail financial position based on the latest SEC disclosures |
Lineage Cell uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Lineage Cell Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Lineage Cell's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Lineage Cell's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 122.47 M.Lineage Cell's profitablity analysis
The company has Profit Margin (PM) of (1.96) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.78) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.78.Determining Lineage Cell's profitability involves analyzing its financial statements and using various financial metrics to determine if Lineage Cell is a good buy. For example, gross profit margin measures Lineage Cell's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Lineage Cell's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Lineage Cell's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lineage Cell Therapeutics. Check Lineage Cell's Beneish M Score to see the likelihood of Lineage Cell's management manipulating its earnings.
Basic technical analysis of Lineage Stock
As of the 27th of March, Lineage Cell secures the Mean Deviation of 3.89, risk adjusted performance of 0.0248, and Downside Deviation of 4.75. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lineage Cell Therapeutics, as well as the relationship between them.Lineage Cell's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lineage Cell insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lineage Cell's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lineage Cell insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lineage Cell's Outstanding Corporate Bonds
Lineage Cell issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Lineage Cell Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Lineage bonds can be classified according to their maturity, which is the date when Lineage Cell Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Lineage Cell's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Lineage Cell's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0248 | |||
| Market Risk Adjusted Performance | 0.1601 | |||
| Mean Deviation | 3.89 | |||
| Semi Deviation | 4.01 | |||
| Downside Deviation | 4.75 | |||
| Coefficient Of Variation | 5167.99 | |||
| Standard Deviation | 5.31 | |||
| Variance | 28.2 | |||
| Information Ratio | 0.0179 | |||
| Jensen Alpha | 0.0943 | |||
| Total Risk Alpha | 0.1082 | |||
| Sortino Ratio | 0.02 | |||
| Treynor Ratio | 0.1501 | |||
| Maximum Drawdown | 24.78 | |||
| Value At Risk | (8.33) | |||
| Potential Upside | 9.43 | |||
| Downside Variance | 22.55 | |||
| Semi Variance | 16.09 | |||
| Expected Short fall | (5.75) | |||
| Skewness | 0.8354 | |||
| Kurtosis | 1.19 |
| Risk Adjusted Performance | 0.0248 | |||
| Market Risk Adjusted Performance | 0.1601 | |||
| Mean Deviation | 3.89 | |||
| Semi Deviation | 4.01 | |||
| Downside Deviation | 4.75 | |||
| Coefficient Of Variation | 5167.99 | |||
| Standard Deviation | 5.31 | |||
| Variance | 28.2 | |||
| Information Ratio | 0.0179 | |||
| Jensen Alpha | 0.0943 | |||
| Total Risk Alpha | 0.1082 | |||
| Sortino Ratio | 0.02 | |||
| Treynor Ratio | 0.1501 | |||
| Maximum Drawdown | 24.78 | |||
| Value At Risk | (8.33) | |||
| Potential Upside | 9.43 | |||
| Downside Variance | 22.55 | |||
| Semi Variance | 16.09 | |||
| Expected Short fall | (5.75) | |||
| Skewness | 0.8354 | |||
| Kurtosis | 1.19 |
Consider Lineage Cell's intraday indicators
Lineage Cell intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Lineage Cell stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Lineage Cell time-series forecasting models is one of many Lineage Cell's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Lineage Cell's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Lineage Stock media impact
Far too much social signal, news, headlines, and media speculation about Lineage Cell that are available to investors today. That information is available publicly through Lineage media outlets and privately through word of mouth or via Lineage internal channels. However, regardless of the origin, that massive amount of Lineage data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lineage Cell news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lineage Cell relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lineage Cell's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lineage Cell alpha.
Lineage Cell Corporate Management
| Charlotte Hubbert | Vice Development | Profile | |
| Jill Howe | CFO Officer | Profile | |
| DVM Dvm | VP Affairs | Profile | |
| Alexandra Hernandez | Senior Controller | Profile | |
| JD III | General Secretary | Profile | |
| Ioana Hone | Director Relations | Profile |
Additional Tools for Lineage Stock Analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.